Yahoo Web Search

Search results

1. • 

     Guselkumab Provides Long-Term Relief From PsA Symptoms

     Medscape· 3 days ago

     Guselkumab improved joint swelling, spinal pain, skin symptoms, and overall disease activity in a...

2. • 

     Stelara biosimilar from Alvotech, Teva approved by FDA

     BioPharma Dive via Yahoo Finance· 2 days ago

     The FDA cleared Selarsdi for treatment of moderate to severe plaque psoriasis and active psoriatic ...

3. • Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

     Morningstar· 3 days ago

     Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis ...

4. • Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment

     Morningstar· 3 days ago

     The treatment is for patients with moderate to severe plaque psoriasis, adults with active psoriatic arthritis and pediatric patients six years and older ...

5. • Plaque psoriasis plagues Marietta man for over 30 years until new treatment

     Fox local via AOL· 4 days ago

     Greg Morrison of Marietta has been struggling with plaque psoriasis and psoriatic arthritis for more than 30 years. Four months ago, he found a new treatment ...

6. • Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...

     KOLR - KSFX Ozarks· 1 day ago

     − Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen ...

7. • 

     FDA Approves Second Ustekinumab Biosimilar

     Medscape· 3 days ago

     The biosimilar is expected to be marketed in the United States on or after February 21, 2025.

8. • Johnson & Johnson (NYSE:JNJ) Shares Sold by BSW Wealth Partners

     ETF DAILY NEWS· 5 days ago

     BSW Wealth Partners decreased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities and ...

9. • Cantargia Publishes New Data on the CAN10 Antibody, Detailing its Interaction with IL1RAP and...

     Digital Journal· 2 days ago

     The CAN10 surrogate also inhibited disease development in models of systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis and peritonitis.

10. • Popular ArthritisPower® Patient Registry Expands Conditions and Becomes PatientSpot™

      Benzinga· 4 days ago

      The Global Healthy Living Foundation (GHLF) is proud to announce a significant leap in its mission to support individuals living with chronic diseases. ArthritisPower, a trusted disease tracking ...